Efficacy and Toxicity of Docetaxel with Cisplatin and Oteracil Potassium (S-1) for Advanced Gastric Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-11001804

Enrollment

Unknown

Registered

2011-12-16

Start date

2007-02-03

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced gastric cancer

Interventions

one:Chemotherapy

Eligibility

Sex/Gender

All

Age

29 Years to 71 Years

Inclusion criteria

Inclusion criteria: Patients had adequate bone, hepatic and renal function. Adequate bone marrow (leukocyte count>3.0*10^9/1, platelet count>100*10^9/1), renal (serum creatinine60ml.min-1 according to Cockroft-Gault formula) and liver(serum bilirubin12 weeks. The score of ECOGPS: 0-1 36 cases, > 1 in 23 cases.

Exclusion criteria

Exclusion criteria: (i) components of S-1 with severe allergies in patients; (ii) patients with an active infection; (iii) severe bone marrow suppression in patients; (iv) severe liver or renal dysfunction in patients; (v) severe comorbidities such as heart disease or lung disease; (vi) mental disorder; (vii) watery diarrhoea; (viii) are receiving flucytosine therapy for patients; (ix) pregnancy or possible pregnancy.

Design outcomes

Primary

Measure	Time frame
Response rate;time to progression;hematologic toxicity;non-hematologic toxicity;	—

Countries

China

Contacts

Public ContactYu Zhong-hua

zhonghua_yu@126.com+86 13702882898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026